Constitutive genetic deletion of the growth regulator nogo-A induces schizophrenia-related endophenotypes

Journal of Neuroscience

Volumn 30, Issue 2, 2010, Pages 556-567

  Willi, Roman ^a,b   Weinmann, Oliver ^a,b   Winter, Christine ^c   Klein, Julia ^c   Sohr, Reinhard ^c   Schnell, Lisa ^a,b   Yee, Benjamin K ^b   Feldon, Joram ^b   Schwab, Martin E ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; PROTEIN NOGO A; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN REGION; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; GENE DELETION; GENETIC DISORDER; GROWTH REGULATION; KNOCKOUT GENE; LATENT INHIBITION; LIMBIC SYSTEM; LOCOMOTION; MALE; MONOAMINERGIC NERVE; NERVE CELL DIFFERENTIATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SENSORIMOTOR FUNCTION; SERODIAGNOSIS; SEROTONIN BRAIN LEVEL; WILD TYPE;

ACOUSTIC STIMULATION; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; INHIBITION (PSYCHOLOGY); INTERPERSONAL RELATIONS; LEARNING; LOCOMOTION; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELIN PROTEINS; NEUROTRANSMITTER AGENTS; PHENOTYPE; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SENSORY GATING; SEQUENCE DELETION;

EID: 74949107496     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4393-09.2010     Document Type: Article

References (85)

1. Abi-Dargham A (2007) Alterations of serotonin transmission in schizophrenia. Int Rev Neurobiol 78:133-164.
2. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (DSM-IV). Washington, DC: APA.
3. Arguello PA, Gogos JA (2006) Modeling madness in mice: one piece at a time. Neuron 52:179-196.
4. Bareyre FM, Haudenschild B, Schwab ME (2002) Long-lasting sprouting and gene expression changes induced by the monoclonal antibody IN-1 in the adult spinal cord. J Neurosci 22:7097-7110.
5. Baruch I, Hemsley DR, Gray JA (1988) Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176:598-606.
6. Blennow K, Bogdanovic N, Gottfries CG, Davidsson P (1999) The growth-associated protein GAP-43 is increased in the hippocampus and in the gyrus cinguli in schizophrenia. J Mol Neurosci 13:101-109.
7. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234-258.
8. Broersen LM, Feldon J, Weiner I (1999) Dissociative effects of apomorphine infusions into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine-induced locomotion. Neuroscience 94:39-46.
9. Budel S, Padukkavidana T, Liu BP, Feng Z, Hu F, Johnson S, Lauren J, Park JH, McGee AW, Liao J, Stillman A, Kim JE, Yang BZ, Sodi S, Gelernter J, Zhao H, Hisama F, Arnsten AF, Strittmatter SM (2008) Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. J Neurosci 28:13161-13172.
10. Buffo A, Zagrebelsky M, Huber AB, Skerra A, Schwab ME, Strata P, Rossi F (2000) Application of neutralizing antibodies against NI-35/250 myelin-associated neurite growth inhibitory proteins to the adult rat cerebellum induces sprouting of uninjured Purkinje cell axons. J Neurosci 20:2275-2286.
11. Carlsson A (2006) The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39 [Suppl 1]:S10-S14.
12. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237-260.
13. Chen J, Lipska BK, Weinberger DR (2006) Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol Psychiatry 59:1180-1188.
14. Coon H, Myles-Worsley M, Tiobech J, Hoff M, Rosenthal J, Bennett P, Reimherr F, Wender P, Dale P, Polloi A, Byerley W (1998) Evidence for a chromosome 2p13-14 schizophrenia susceptibility locus in families from Palau, Micronesia. Mol Psychiatry 3:521-527.
15. Crider A (1997) Perseveration in schizophrenia. Schizophr Bull 23:63-74.
16. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V (2003) White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60:443-456.
17. Dimou L, Schnell L, Montani L, Duncan C, Simonen M, Schneider R, Liebscher T, Gullo M, Schwab ME (2006) Nogo-A-deficient mice reveal strain-dependent differences in axonal regeneration. J Neurosci 26:5591-5603.
18. Dodd DA, Niederoest B, Bloechlinger S, Dupuis L, Loeffler JP, Schwab ME (2005) Nogo-A, -B, and -C are found on the cell surface and interact together in many different cell types. J Biol Chem 280:12494-12502.
19. Ellenbroek BA, Budde S, Cools AR (1996) Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex. Neuroscience 75:535-542.
20. Enard W, Gehre S, Hammerschmidt K, Hölter SM, Blass T, Somel M, Brückner MK, Schreiweis C, Winter C, Sohr R, Becker L, Wiebe V, Nickel B, Giger T, Müller U, Groszer M, Adler T, Aguilar A, Bolle I, Calzada-Wack J, et al (2009) A humanized version of Foxp2 affects cortico-basal ganglia circuits in mice. Cell 137:961-971.
21. Fone KC, Porkess MV (2008) Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev 32:1087-1102.
22. Fritschy JM, Mohler H (1995) GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J Comp Neurol 359:154-194.
23. Grace AA (1993) Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm 91:111-134.
24. Gray NS, Hemsley DR, Gray JA (1992) Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol Psychiatry Brain Res 1:83-89.
25. Hagenbuch N, Feldon J, Yee BK (2006) Use of the elevated plus-maze test with opaque or transparent walls in the detection of mouse strain differences and the anxiolytic effects of diazepam. Behav Pharmacol 17:31-41.
26. Harrison PJ (1997) Schizophrenia: a disorder of neurodevelopment? Curr Opin Neurobiol 7:285-289.
27. Harrison PJ (1999) The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122:593-624.
28. Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10:40-68.
29. Hirvonen J, van Erp TG, Huttunen J, Aalto S, Någren K, Huttunen M, Lönnqvist J, Kaprio J, Hietala J, Cannon TD (2005) Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 62:371-378.
30. Hoffman HS, Searle JL (1965) Acoustic variables in the modification of startle reaction in the rat. J Comp Physiol Psychol 60:53-58.
31. Hsu R, Woodroffe A, Lai WS, Cook MN, Mukai J, Dunning JP, Swanson DJ, Roos JL, Abecasis GR, Karayiorgou M, Gogos JA (2007) Nogo Receptor 1 (RTN4R) as a candidate gene for schizophrenia: analysis using human and mouse genetic approaches. PLoS One 2:e1234.
32. Huber AB, Weinmann O, Brösamle C, Oertle T, Schwab ME (2002) Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. J Neurosci 22:3553-3567.
33. Karoutzou G, Emrich HM, Dietrich DE (2008) The myelin-pathogenesis puzzle in schizophrenia: a literature review. Mol Psychiatry 13:245-260.
34. Keshavan MS, Hogarty GE (1999) Brain maturational processes and delayed onset in schizophrenia. Dev Psychopathol 11:525-543.
35. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lübbert H, Bujard H (1996) Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A 93:10933-10938.
36. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93:9235-9240.
37. Lewis DA, Levitt P (2002) Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25:409-432.
38. Lewis DA, Lieberman JA (2000) Catching up on schizophrenia: natural history and neurobiology. Neuron 28:325-334.
39. Lipska BK, Weinberger DR (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23:223-239.
40. Lipska BK, Lerman DN, Khaing ZZ, Weinberger DR (2003) The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain. Eur J Neurosci 18:3097-3104.
41. Liu H, Abecasis GR, Heath SC, Knowles A, Demars S, Chen YJ, Roos JL, Rapoport JL, Gogos JA, Karayiorgou M (2002) Genetic variation in the 22q11 locus and susceptibility to schizophrenia. Proc Natl Acad Sci U S A 99:16859-16864.
42. Lubow RE, Moore AU (1959) Latent inhibition: the effect of nonreinforced pre-exposure to the conditional stimulus. J Comp Physiol Psychol 52:415-419.
43. Marek GJ (2007) Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development. Int Rev Neurobiol 78:165-192.
44. McGee AW, Yang Y, Fischer QS, Daw NW, Strittmatter SM (2005) Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor. Science 309:2222-2226.
45. Meyer U, Feldon J, Schedlowski M, Yee BK (2005) Towards an immunoprecipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 29:913-947.
46. Meyer U, Nyffeler M, Engler A, Urwyler A, Schedlowski M, Knuesel I, Yee BK, Feldon J (2006) The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci 26:4752-4762.
47. Meyer U, Yee BK, Feldon J (2007) The neurodevelopmental impact of prenatal infections at different times of pregnancy: the earlier the worse? Neuroscientist 13:241-256.
48. Meyer U, Nyffeler M, Schwendener S, Knuesel I, Yee BK, Feldon J (2008) Relative prenatal and postnatal maternal contributions to schizophreniarelated neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology 33:441-456.
49. Mingorance-Le Meur A, Zheng B, Soriano E, del Río JA (2007) Involvement of the myelin-associated inhibitor Nogo-A in early cortical development and neuronal maturation. Cereb Cortex 17:2375-2386.
50. Moy SS, Nadler JJ, Young NB, Nonneman RJ, Grossman AW, Murphy DL, D'Ercole AJ, Crawley JN, Magnuson TR, Lauder JM (2009) Social approach in genetically engineered mouse lines relevant to autism. Genes Brain Behav 8:129-142.
51. Novak G, Kim D, Seeman P, Tallerico T (2002) Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert. Mol Brain Res 107:183-189.
52. O'Donnell P, Grace AA (1998) Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr Bull 24:267-283.
53. Perrone-Bizzozero NI, Sower AC, Bird ED, Benowitz LI, Ivins KJ, Neve RL (1996) Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc Natl Acad Sci U S A 93:14182-14187.
54. Perry W, Minassian A, Lopez B, Maron L, Lincoln A (2007) Sensorimotor gating deficits in adults with autism. Biol Psychiatry 61:482-486.
55. Powell CM, Miyakawa T (2006) Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biol Psychiatry 59:1198-1207.
56. Prinssen EP, Assié MB, Koek W, Kleven MS (2002) Depletion of 5-HT disrupts prepulse inhibition in rats: dependence on the magnitude of depletion, and reversal by a 5-HT precursor. Neuropsychopharmacology 26:340-347.
57. Rapoport JL, Addington AM, Frangou S, PsychMR (2005) The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10:434-449.
58. Ridley RM (1994) The psychology of perserverative and stereotyped behaviour. Prog Neurobiol 44:221-231.
59. Roffler-Tarlov S, Graybiel AM (1984) Weaver mutation has differential effects on the dopamine-containing innervation of the limbic and nonlimbic striatum. Nature 307:62-66.
60. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT (2006) Neurobiology of schizophrenia. Neuron 52:139-153.
61. Rothermundt M, Falkai P, Ponath G, Abel S, Bürkle H, Diedrich M, Hetzel G, Peters M, Siegmund A, Pedersen A, Maier W, Schramm J, Suslow T, Ohrmann P, Arolt V (2004) Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 9:897-899.
62. Salahpour A, Ramsey AJ, Medvedev IO, Kile B, Sotnikova TD, Holmstrand E, Ghisi V, Nicholls PJ, Wong L, Murphy K, Sesack SR, Wightman RM, Gainetdinov RR, Caron MG (2008) Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proc Natl Acad Sci U S A 105:4405-4410.
63. Schwab ME (2004) Nogo and axon regeneration. Curr Opin Neurobiol 14:118-124.
64. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133-152.
65. Seeman P, Kapur S (2000) Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci U S A 97:7673-7675.
66. Shaw SH, Kelly M, Smith AB, Shields G, Hopkins PJ, Loftus J, Laval SH, Vita A, De Hert M, Cardon LR, Crow TJ, Sherrington R, DeLisi LE (1998) A genome-wide search for schizophrenia susceptibility genes. Am J Med Genet 81:364-376.
67. Shen S, Lang B, Nakamoto C, Zhang F, Pu J, Kuan SL, Chatzi C, He S, Mackie I, Brandon NJ, Marquis KL, Day M, Hurko O, McCaig CD, Riedel G, St ClairD (2008) Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. J Neurosci 28:10893-10904.
68. Sheu FS, Azmitia EC, Marshak DR, Parker PJ, Routtenberg A (1994) Glialderived S100b protein selectively inhibits recombinant beta protein kinase C (PKC) phosphorylation of neuron-specific protein F1/GAP43. Mol Brain Res 21:62-66.
69. Simonen M, Pedersen V, Weinmann O, Schnell L, Buss A, Ledermann B, Christ F, Sansig G, van der Putten H, Schwab ME (2003) Systemic deletion of the myelin-associated outgrowth inhibitor Nogo-A improves regenerative and plastic responses after spinal cord injury. Neuron 38:201-211.
70. Sinibaldi L, De Luca A, Bellacchio E, Conti E, Pasini A, Paloscia C, Spalletta G, Caltagirone C, Pizzuti A, Dallapiccola B (2004) Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. Hum Mutat 24:534-535.
71. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH (2007) Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 27:10695-10702.
72. Sturrock RR (1980) A developmental study of the mouse neostriatum. J Anat 130:243-261.
73. Takahashi H, Higuchi M, Suhara T (2006) The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol Psychiatry 59:919-928.
74. Tan EC, Chong SA, Wang H, Chew-Ping Lim E, Teo YY (2005) Genderspecific association of insertion/deletion polymorphisms in the nogo gene and chronic schizophrenia. Mol Brain Res 139:212-216.
75. Voorn P, Kalsbeek A, Jorritsma-Byham B, Groenewegen HJ (1988) The preand postnatal development of the dopaminergic cell groups in the ventral mesencephalon and the dopaminergic innervation of the striatum of the rat. Neuroscience 25:857-887.
76. Wang X, Chun SJ, Treloar H, Vartanian T, Greer CA, Strittmatter SM (2002) Localization of Nogo-A and Nogo-66 receptor proteins at sites of axonmyelin and synaptic contact. J Neurosci 22:5505-5515.
77. Wang Y, O'MalleyBWJr, Tsai SY, O'MalleyBW (1994) A regulatory system for use in gene transfer. Proc Natl Acad Sci U S A 91:8180-8184.
78. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669.
79. Weinmann O, Schnell L, Ghosh A, Montani L, Wiessner C, Wannier T, Rouiller E, Mir A, Schwab ME (2006) Intrathecally infused antibodies against Nogo-A penetrate the CNS and downregulate the endogenous neurite growth inhibitor Nogo-A. Mol Cell Neurosci 32:161-173.
80. Willi R, Aloy EM, Yee BK, Feldon J, Schwab ME (2009) Behavioral characterization of mice lacking the neurite outgrowth inhibitor Nogo-A. Genes Brain Behav 8:181-192.
81. Winter C, Djodari-Irani A, Sohr R, Morgenstern R, Feldon J, Juckel G, Meyer U (2009) Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int J Neuropsychopharmacol 12:513-524.
82. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, Branchek T, Gerald CP (2007) The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 6:628-639.
83. Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JK, Malat J, Williams JA, O'Tuama LA, Snyder SH, Kuhar MJ, Gjedde A (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234:1558-1563.
84. Yee BK, Balic E, Singer P, Schwerdel C, Grampp T, Gabernet L, Knuesel I, Benke D, Feldon J, Mohler H, Boison D (2006) Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J Neurosci 26:3169-3181.
85. Yiu G, He Z (2006) Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 7:617-627.